Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Regeneron Pharmaceuticals and Sanofi SA have initiated a new clinical study titled ‘An Open-Label, Single-Arm Study to Assess Growth and Bone Mineral Density in Children ≥6 to ...

Greater baseline disease pruritus and quality of life impairment are associated with higher rates of super response to dupilumab in patients with AD.

Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...

Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement ...

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults ...

Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

NASHVILLE, Tennessee — For children with uncontrolled asthma on standard therapies and meeting criteria of a type 2 (T2) inflammatory phenotype, a prospective 1-year extension from a phase 3 trial ...